TC
OPNT

TAP Consulting’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

TAP Consulting’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-471
Closed -$16K – 573
2021
Q4 		$16K Buy
+471
New +$13.1K ﹤0.01% 379

Other funds holding OPNT

Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
OCM
Ovata Capital Management Hong Kong $1.33B AUM 5.69% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TAP Consulting's OPNT Position: Q1 2022 in Review

TAP Consulting sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2022, closing a stake of 471 shares — an estimated $16K sold.

TAP Consulting first reported a position in OPNT in Q4 2021 and held it in 1 quarter. The position peaked at $16K in Q4 2021. 41 funds tracked by Wall St. Rank hold OPNT as of Q1 2022.

  • TAP Consulting reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • TAP Consulting sold 471 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $16K.
  • TAP Consulting first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • TAP Consulting's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $16K in Q4 2021.
  • 41 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on TAP Consulting's 13F filing for Q1 2022, filed 26 Apr 2022.